Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities research analysts at Jefferies Group lowered their FY2017 earnings per share estimates for Vanda Pharmaceuticals in a research note issued to investors on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will earn ($0.52) per share for the year, down from their prior forecast of ($0.51). Jefferies Group currently has a “Buy” rating and a $21.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ FY2018 earnings at ($0.33) EPS.

Other equities research analysts have also issued reports about the company. Zacks Investment Research raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. HC Wainwright started coverage on Vanda Pharmaceuticals in a report on Friday, May 26th. They issued a “buy” rating and a $18.00 target price for the company. BidaskClub lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Piper Jaffray Companies set a $23.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Oppenheimer Holdings, Inc. set a $21.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $21.25.

ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/31/jefferies-group-equities-analysts-reduce-earnings-estimates-for-vanda-pharmaceuticals-inc-vnda.html.

Shares of Vanda Pharmaceuticals (NASDAQ VNDA) opened at 16.85 on Thursday. The firm has a 50-day moving average price of $16.10 and a 200 day moving average price of $14.88. The stock’s market capitalization is $755.86 million. Vanda Pharmaceuticals has a one year low of $12.70 and a one year high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The firm had revenue of $42.06 million during the quarter, compared to the consensus estimate of $40.31 million. During the same period in the prior year, the company earned $0.01 EPS. The firm’s revenue was up 16.7% compared to the same quarter last year.

Hedge funds have recently made changes to their positions in the company. Rice Hall James & Associates LLC raised its stake in shares of Vanda Pharmaceuticals by 1.0% in the second quarter. Rice Hall James & Associates LLC now owns 27,903 shares of the biopharmaceutical company’s stock valued at $455,000 after buying an additional 279 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Vanda Pharmaceuticals by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 45,562 shares of the biopharmaceutical company’s stock valued at $638,000 after buying an additional 541 shares in the last quarter. American International Group Inc. raised its stake in shares of Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after buying an additional 1,491 shares in the last quarter. Algert Global LLC raised its stake in shares of Vanda Pharmaceuticals by 11.8% in the first quarter. Algert Global LLC now owns 18,223 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,927 shares in the last quarter. Finally, Strs Ohio raised its stake in shares of Vanda Pharmaceuticals by 4.6% in the first quarter. Strs Ohio now owns 49,600 shares of the biopharmaceutical company’s stock valued at $694,000 after buying an additional 2,200 shares in the last quarter. Institutional investors and hedge funds own 86.49% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.